- World Bipolar Day marks the launch of EIT Health-supported EDIT-B’s ground-breaking diagnostic test to differentiate between depression and bipolar disorder in France.
- With no equivalent on the market, the main objective of the myEDIT-B® blood test is to provide objective biological data to complement the psychiatrist’s assessment and reduce the delay in diagnosis from an average of 8 years to just four weeks.
- EIT Health facilitated a robust consortium for the EDIT-B project, supporting the consortium to fast-track their innovation to market, first in Italy and now France.
- EIT Health solidifies its status as a driving force for meaningful impact in healthcare innovation.
On 30 March 2024, EIT Health announces the launch in France of consortium, EDIT-B’s, innovative blood diagnostic test to differentiate between depression and bipolar disorder. The EIT Health supported consortium, led by ALCEDIAG, is now working to ensure the solution reaches more countries in Europe and beyond to help healthcare professionals improve the diagnostic outcomes for millions of people living with bipolar disorder.